Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-241751 in Adult Participants With Major Depressive Disorder
NCT03586427Phase 2Completed
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zelquistinel in major depressive disorder (MDD). Started Jun 2018; status: completed.
02
Drugs
zelquistinel
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03586427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586427.